SERINC3 and SERINC5 Restrict HIV-1 Infectivity and Are Counteracted by Nef

Overview

Journal Nature

Specialty Science

Date 2015 Sep 30

PMID 26416733

Citations 276

Authors

Yoshiko Usami

Yuanfei Wu

Heinrich G Gottlinger

Affiliations

Soon will be listed here.

Abstract

HIV-1 Nef and the unrelated mouse leukaemia virus glycosylated Gag (glycoGag) strongly enhance the infectivity of HIV-1 virions produced in certain cell types in a clathrin-dependent manner. Here we show that Nef and glycoGag prevent the incorporation of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and SERINC5 into HIV-1 virions to an extent that correlates with infectivity enhancement. Silencing of both SERINC3 and SERINC5 precisely phenocopied the effects of Nef and glycoGag on HIV-1 infectivity. The infectivity of nef-deficient virions increased more than 100-fold when produced in double-knockout human CD4(+) T cells that lack both SERINC3 and SERINC5, and re-expression experiments confirmed that the absence of SERINC3 and SERINC5 accounted for the infectivity enhancement. Furthermore, SERINC3 and SERINC5 together restricted HIV-1 replication, and this restriction was evaded by Nef. SERINC3 and SERINC5 are highly expressed in primary human HIV-1 target cells, and inhibiting their downregulation by Nef is a potential strategy to combat HIV/AIDS.

Citing Articles

The Role of Sustained Type I Interferon Secretion in Chronic HIV Pathogenicity: Implications for Viral Persistence, Immune Activation, and Immunometabolism.

Teer E, Mukonowenzou N, Essop M Viruses. 2025; 17(2).

PMID: 40006894 PMC: 11860620. DOI: 10.3390/v17020139.

SERINC5 counters retroviruses and non-retroviruses.

Yu J, Liu C, Qu X, Gao X, Liu Y Front Cell Infect Microbiol. 2025; 14:1516806.

PMID: 39902183 PMC: 11788155. DOI: 10.3389/fcimb.2024.1516806.

HIV-1 and BLV are insensitive to SERINC5 restriction under the cell-cell infection.

Yu C, Jiang F, Li Y, Li Q, Tokunaga K, Yang D Microbiol Spectr. 2025; 13(3):e0274824.

PMID: 39868869 PMC: 11878069. DOI: 10.1128/spectrum.02748-24.

Equine Infectious Anemia Virus Cellular Partners Along the Viral Cycle.

Schimmich C, Vabret A, Zientara S, Valle-Casuso J Viruses. 2025; 17(1).

PMID: 39861793 PMC: 11769393. DOI: 10.3390/v17010005.

Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategies.

Dzhivhuho G, Jackson P, Honeycutt E, da Silva Mesquita F, Huang J, Hammarskjold M bioRxiv. 2025; .

PMID: 39829859 PMC: 11741256. DOI: 10.1101/2025.01.06.631466.

References

Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M . Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science. 2012; 338(6106):524-8. DOI: 10.1126/science.1226359. View

Miller M, Warmerdam M, Gaston I, Greene W, Feinberg M . The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med. 1994; 179(1):101-13. PMC: 2191317. DOI: 10.1084/jem.179.1.101. View

Aiken C . Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol. 1997; 71(8):5871-7. PMC: 191842. DOI: 10.1128/JVI.71.8.5871-5877.1997. View

Accola M, Strack B, Gottlinger H . Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol. 2000; 74(12):5395-402. PMC: 112023. DOI: 10.1128/jvi.74.12.5395-5402.2000. View

Usami Y, Popov S, Gottlinger H . The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex. J Virol. 2014; 88(6):3443-54. PMC: 3957955. DOI: 10.1128/JVI.01933-13. View

Collins K, Chen B, Kalams S, Walker B, Baltimore D . HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998; 391(6665):397-401. DOI: 10.1038/34929. View

Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene W . HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology. 2004; 328(1):36-44. DOI: 10.1016/j.virol.2004.07.015. View

Rhee S, Marsh J . Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol. 1994; 68(8):5156-63. PMC: 236459. DOI: 10.1128/JVI.68.8.5156-5163.1994. View

Lama J, Mangasarian A, Trono D . Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol. 1999; 9(12):622-31. DOI: 10.1016/s0960-9822(99)80284-x. View

10.

Prats A, de Billy G, Wang P, Darlix J . CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. J Mol Biol. 1989; 205(2):363-72. DOI: 10.1016/0022-2836(89)90347-1. View

11.

Sougrat R, Bartesaghi A, Lifson J, Bennett A, Bess J, Zabransky D . Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 2007; 3(5):e63. PMC: 1864992. DOI: 10.1371/journal.ppat.0030063. View

12.

Luo T, Douglas J, Livingston R, Garcia J . Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology. 1998; 241(2):224-33. DOI: 10.1006/viro.1997.8966. View

13.

COHEN G, Gandhi R, Davis D, Mandelboim O, Chen B, Strominger J . The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999; 10(6):661-71. DOI: 10.1016/s1074-7613(00)80065-5. View

14.

Pizzato M . MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. Proc Natl Acad Sci U S A. 2010; 107(20):9364-9. PMC: 2889076. DOI: 10.1073/pnas.1001554107. View

15.

Abacioglu Y, Fouts T, Laman J, Claassen E, Pincus S, Moore J . Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses. 1994; 10(4):371-81. DOI: 10.1089/aid.1994.10.371. View

16.

Inuzuka M, Hayakawa M, Ingi T . Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. J Biol Chem. 2005; 280(42):35776-83. DOI: 10.1074/jbc.M505712200. View

17.

Cohen F, Melikyan G . The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement. J Membr Biol. 2004; 199(1):1-14. DOI: 10.1007/s00232-004-0669-8. View

18.

Akagi T, Shishido T, Murata K, Hanafusa H . v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc Natl Acad Sci U S A. 2000; 97(13):7290-5. PMC: 16538. DOI: 10.1073/pnas.140210297. View

19.

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

20.

Schindler M, Munch J, Kutsch O, Li H, Santiago M, Bibollet-Ruche F . Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell. 2006; 125(6):1055-67. DOI: 10.1016/j.cell.2006.04.033. View